Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631044 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
A Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 387
- Enrollment target
NCT02631044 is a Phase 1 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 387 participants.
The verdict
NCT02631044, a Phase 1 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 387 participants
- Enrollment target
Study Summary
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.
Interventions
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) single-dose schedule
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631044
The ClinicalTrials.gov registry entry for NCT02631044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, a Subsidiary of Celgene, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JCAR017 (lisocabtagene maraleucel) single-dose schedule is the first listed.
NCT02631044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631044 about?
NCT02631044 is a clinical study titled "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)". This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We wi...
What is the current status of trial NCT02631044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2016-01-06. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT02631044?
The interventions under investigation include: JCAR017 (lisocabtagene maraleucel) single-dose schedule (BIOLOGICAL), JCAR017 (lisocabtagene maraleucel) 2-dose schedule (BIOLOGICAL).
Who is sponsoring clinical trial NCT02631044?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.